Anti-candida, anti-coagulant and thrombolytic activities of biosynthesized silver nanoparticles using cell-free extract of Bacillus safensis LAU 13

- Biogenic synthesis of AgNPs by a strain of Bacillus safensis.
- Demonstration of the anti-candida activity of AgNPs with MIC of 40 μg/ml.
- Potent anti-coagulant and thrombolytic activities of AgNPs were obtained.
- Proposed mechanisms of thrombolytic activity of AgNPs presented.

This study reports potent anti-candida, blood anti-coagulant and thrombolytic activities of silver nanoparticles (AgNPs) biosynthesized using cell-free extract of Bacillus safensis LAU 13 (GenBank accession number KJ461434). The AgNPs was characterized using UV-vis spectroscopy, Fourier-transform infrared spectroscopy, and Transmission electron microscopy. The AgNPs had λmax of 419 nm; with FTIR peaks at 3308, 2359, 1636, and 422 cm−1, which indicated the involvement of proteins as the capping and stabilization molecules in the synthesis of AgNPs. The TEM analysis showed that biosynthesized nanoparticles were fairly spherical having size of 5-95 nm, with silver as the prominent metal from the energy dispersive X-ray (EDX) analysis. The particles depicted the characteristic crystalline face-centred cubic phase of AgNPs from the selected area electron diffraction (SAED) analysis. The AgNPs effectively inhibited a clinical isolate of Candida albicans with MIC of 40 μg/ml, prevented coagulation of human blood, and also completely dissolved human blood clot (thrombus) as obtained through light microscopy. This work has further shown that the biosynthesized AgNPs has potent biomedical activities which can find useful applications in diverse areas, particularly in the management of blood coagulation disorders. The report adds to growing biotechnological relevance of B. safensis in the field of nanotechnology.

117